Wird geladen...
New therapies for von Willebrand disease
The management of von Willebrand disease (VWD) is based upon the dual correction of the primary hemostasis defect, due to the inherited deficiency of von Willebrand factor (VWF), and of the secondary defect of factor VIII coagulant activity (FVIII:C), due to the loss of binding and stabilization by...
Gespeichert in:
| Veröffentlicht in: | Blood Adv |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society of Hematology
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6855108/ https://ncbi.nlm.nih.gov/pubmed/31714963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000368 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|